The estimated Net Worth of Groot Eleanor De is at least $893 ezer dollars as of 22 December 2021. Dr De owns over 20,132 units of Alaunos Therapeutics Inc stock worth over $206,282 and over the last 5 years he sold ZIOP stock worth over $197,624. In addition, he makes $488,980 as Exec. VP of Operations at Alaunos Therapeutics Inc.
Sign up
Dr D ZIOP stock SEC Form 4 insiders trading
Dr has made over 3 trades of the Alaunos Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 20,132 units of ZIOP stock worth $25,568 on 22 December 2021.
The largest trade he's ever made was selling 24,890 units of Alaunos Therapeutics Inc stock on 2 January 2020 worth over $113,250. On average, Dr trades about 13,328 units every 144 days since 2020. As of 22 December 2021 he still owns at least 237,106 units of Alaunos Therapeutics Inc stock.
You can see the complete history of Dr De stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Eleanor de Groot Ph.D. biography
Dr. Eleanor de Groot Ph.D. is the Exec. VP of Operations at Alaunos Therapeutics Inc.
What is the salary of Dr D?
As the Exec. VP of Operations of Alaunos Therapeutics Inc, the total compensation of Dr D at Alaunos Therapeutics Inc is $488,980. There are 5 executives at Alaunos Therapeutics Inc getting paid more, with Laurence Cooper having the highest compensation of $3,317,570.
How old is Dr D?
Dr D is 52, he's been the Exec. VP of Operations of Alaunos Therapeutics Inc since . There are 11 older and 5 younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.
What's Dr D's mailing address?
Groot's mailing address filed with the SEC is C/O ZIOPHARM ONCOLOGY, INC., 8030 EL RIO ST., HOUSTON, TX, 77054.
Insiders trading at Alaunos Therapeutics Inc
Over the last 18 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk és Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.
What does Alaunos Therapeutics Inc do?
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
What does Alaunos Therapeutics Inc's logo look like?
Complete history of Dr De stock trades at Alaunos Therapeutics Inc
Alaunos Therapeutics Inc executives and stock owners
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Laurence Cooper,
Chief Executive Officer, Director -
Satyavrat Shukla,
Chief Financial Officer -
Robert Hadfield,
Executive Vice President, Chief Compliance Officer, General Counsel, Secretary -
Kevin Lafond,
Senior Vice President - Finance, Chief Accounting Officer, Treasurer -
Heidi Hagen,
Independent Director -
Dr. Eleanor de Groot Ph.D.,
Exec. VP of Operations -
Christopher Bowden,
Independent Director -
Scott Tarriff,
Independent Chairman of the Board -
Dr. Raffaele Baffa M.D., Ph.D.,
Chief Medical Officer and Exec. VP of R&D -
Elan Ezickson,
Independent Director -
Zuie-Chin Huang M.B.A.,
Exec. Chairman -
Mary Thistle,
Independent Director -
Raffaele Baffa,
Chief Medical Officer -
Christopher Taylor,
Vice President, Investor Relations and Corporate Communications -
James Huang,
Director -
J. Kevin Buchi,
Director -
Lynn Ferrucci,
Executive Vice President of Human Resources, Facilities, Administration and IT -
Eleanor De Groot,
Executive Vice President, General Manager, Cell Therapy -
Jill Buck,
Executive Vice President, General Manager, Gene Therapy -
Dr. Drew Deniger,
Head of TCR-T Cell Therapy Program -
Dr. David M. Mauney M.D.,
Consultant -
Melinda Lackey,
Sr. VP of Legal -
Michael Wong,
VP of Fin. & Principal Accounting Officer -
Timothy M. Cunningham CPA, M.B.A.,
Interim CFO & Principal Financial Officer -
Kevin S. Boyle Sr.,
CEO & Director -
James Anthony Cannon,
Director -
Randal Jintrexon Corp Kirk,
-
Murray Brennan,
Director -
Wyche Fowler,
Director -
Randal J Kirk,
Director -
Caesar J Belbel,
COO, CLO, and Secretary -
Michael Weiser,
Director -
Francois Lebel,
Executive Vice President R&D -
David M Md Mauney,
President -
Douglas W. Pagan,
Director -
Scott Braunstein,
Director -
Hagop Youssoufian,
Executive VP, CMO -
Timothy Mcinerney,
Director -
Jonathan Lewis,
CEO -
Jason Amello,
Executive Vice President & CFO -
Richard E Bagley,
President, COO & Treasurer -
George B Abercrombie,
Director -
Robert Peter Gale,
Senior V.P. of Research -
Lindsay A Md Rosenwald,
10% owner -
Woodlands Health Ventures F...,
10% owner -
Gary S Fragin,
Director -
Sath Shukla,
EVP, Chief Financial Officer -
Jaime Vieser,
Director -
Holger Weis,
Director -
Robert W Postma,
Director -
Kevin S. Sr. Boyle,
Chief Executive Officer -
Melinda Lackey,
Senior Vice President, Legal